vs
Side-by-side financial comparison of FIBROGEN INC (KYNB) and Americas Gold & Silver Corp (USAS). Click either name above to swap in a different company.
FIBROGEN INC is the larger business by last-quarter revenue ($25.4M vs $19.1M, roughly 1.3× Americas Gold & Silver Corp). Americas Gold & Silver Corp runs the higher net margin — -82.3% vs -129.8%, a 47.5% gap on every dollar of revenue. On growth, Americas Gold & Silver Corp posted the faster year-over-year revenue change (-28.0% vs -29.9%). Americas Gold & Silver Corp produced more free cash flow last quarter ($-41.3M vs $-59.3M).
FibroGen Inc. is a biopharmaceutical firm developing and commercializing innovative therapies for unmet medical needs, targeting fibrotic diseases, anemia and cancer. Its lead product roxadustat is approved in multiple markets including China and Japan, serving patients across key therapeutic segments.
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
KYNB vs USAS — Head-to-Head
Income Statement — Q1 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.4M | $19.1M |
| Net Profit | $-32.9M | $-15.7M |
| Gross Margin | 15.9% | 34.2% |
| Operating Margin | -193.9% | — |
| Net Margin | -129.8% | -82.3% |
| Revenue YoY | -29.9% | -28.0% |
| Net Profit YoY | 57.1% | 2.8% |
| EPS (diluted) | $-0.33 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $19.1M | ||
| Q3 24 | — | $26.5M | ||
| Q1 24 | $25.4M | — | ||
| Q4 23 | $-73.8M | — | ||
| Q3 23 | $40.1M | — | ||
| Q2 23 | $44.3M | — | ||
| Q1 23 | $36.2M | — | ||
| Q4 22 | $34.4M | — |
| Q3 25 | — | $-15.7M | ||
| Q3 24 | — | $-16.2M | ||
| Q1 24 | $-32.9M | — | ||
| Q4 23 | $-56.2M | — | ||
| Q3 23 | $-63.6M | — | ||
| Q2 23 | $-87.7M | — | ||
| Q1 23 | $-76.7M | — | ||
| Q4 22 | $-66.2M | — |
| Q3 25 | — | 34.2% | ||
| Q3 24 | — | 23.6% | ||
| Q1 24 | 15.9% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | 89.4% | — | ||
| Q2 23 | 87.1% | — | ||
| Q1 23 | 90.3% | — | ||
| Q4 22 | 85.7% | — |
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | -193.9% | — | ||
| Q4 23 | 128.8% | — | ||
| Q3 23 | -158.2% | — | ||
| Q2 23 | -198.7% | — | ||
| Q1 23 | -210.4% | — | ||
| Q4 22 | -192.5% | — |
| Q3 25 | — | -82.3% | ||
| Q3 24 | — | -60.9% | ||
| Q1 24 | -129.8% | — | ||
| Q4 23 | 76.2% | — | ||
| Q3 23 | -158.5% | — | ||
| Q2 23 | -197.8% | — | ||
| Q1 23 | -212.1% | — | ||
| Q4 22 | -192.6% | — |
| Q3 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | $-0.33 | — | ||
| Q4 23 | $-0.56 | — | ||
| Q3 23 | $-0.65 | — | ||
| Q2 23 | $-0.90 | — | ||
| Q1 23 | $-0.81 | — | ||
| Q4 22 | $-0.70 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.6M | $39.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-228.1M | $50.2M |
| Total Assets | $365.9M | $234.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $39.1M | ||
| Q3 24 | — | — | ||
| Q1 24 | $177.6M | — | ||
| Q4 23 | $203.5M | — | ||
| Q3 23 | $251.3M | — | ||
| Q2 23 | $335.7M | — | ||
| Q1 23 | $355.9M | — | ||
| Q4 22 | $422.0M | — |
| Q3 25 | — | $50.2M | ||
| Q3 24 | — | $53.1M | ||
| Q1 24 | $-228.1M | — | ||
| Q4 23 | $-204.2M | — | ||
| Q3 23 | $-157.2M | — | ||
| Q2 23 | $-102.3M | — | ||
| Q1 23 | $-48.9M | — | ||
| Q4 22 | $-21.4M | — |
| Q3 25 | — | $234.7M | ||
| Q3 24 | — | — | ||
| Q1 24 | $365.9M | — | ||
| Q4 23 | $423.5M | — | ||
| Q3 23 | $460.4M | — | ||
| Q2 23 | $515.1M | — | ||
| Q1 23 | $538.5M | — | ||
| Q4 22 | $610.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-59.3M | $-12.5M |
| Free Cash FlowOCF − Capex | $-59.3M | $-41.3M |
| FCF MarginFCF / Revenue | -233.9% | -216.5% |
| Capex IntensityCapex / Revenue | 0.1% | 150.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-274.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-12.5M | ||
| Q3 24 | — | $2.4M | ||
| Q1 24 | $-59.3M | — | ||
| Q4 23 | $-18.3M | — | ||
| Q3 23 | $-84.5M | — | ||
| Q2 23 | $-110.6M | — | ||
| Q1 23 | $-101.6M | — | ||
| Q4 22 | $-52.5M | — |
| Q3 25 | — | $-41.3M | ||
| Q3 24 | — | $-11.2M | ||
| Q1 24 | $-59.3M | — | ||
| Q4 23 | $-18.6M | — | ||
| Q3 23 | $-85.2M | — | ||
| Q2 23 | $-111.6M | — | ||
| Q1 23 | $-102.2M | — | ||
| Q4 22 | $-52.8M | — |
| Q3 25 | — | -216.5% | ||
| Q3 24 | — | -42.2% | ||
| Q1 24 | -233.9% | — | ||
| Q4 23 | 25.2% | — | ||
| Q3 23 | -212.3% | — | ||
| Q2 23 | -251.7% | — | ||
| Q1 23 | -282.6% | — | ||
| Q4 22 | -153.8% | — |
| Q3 25 | — | 150.8% | ||
| Q3 24 | — | 51.2% | ||
| Q1 24 | 0.1% | — | ||
| Q4 23 | -0.3% | — | ||
| Q3 23 | 1.7% | — | ||
| Q2 23 | 2.2% | — | ||
| Q1 23 | 1.6% | — | ||
| Q4 22 | 1.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KYNB
| Drug Product Revenue | $24.5M | 97% |
| Other | $878.0K | 3% |
USAS
Segment breakdown not available.
